BACKGROUND: Rare mutations in nephrosis 2 (NPHS2), encoding podocin, are found in patients with familial and sporadic steroid-resistant nephrotic syndrome and focal segmental glomerular sclerosis. The objective of this study is to assess the contribution of the commonly reported functional podocin polymorphism R229Q to kidney disease in the population at large and replicate a prior study of an association of R229Q and albuminuria in the general population. STUDY DESIGN: Large sample of the Atherosclerosis Risk in Communities (ARIC) Study, a population-based prospective study. SETTING & PARTICIPANTS: 4,424 white and 3,746 black middle-aged adults. PREDICTOR: Genotype at the R229Q polymorphism in podocin. OUTCOMES: Urinary albumin-creatinine ratio (ACR) and decreased estimated glomerular filtration rate (eGFR) as measures of kidney damage/dysfunction. MEASUREMENTS: Crude and multivariable adjusted linear and logistic regression models. RESULTS: R229Q allele frequencies were 3.7% in 4,424 white and 0.6% in 3,746 black individuals. No significant association of R229Q with increased ACR or decreased eGFR was observed (adjusted odds ratio of ACR > or = 30 mg/g in RQ/QQ versus RR carriers, 1.18; 95% confidence interval, 0.76 to 1.84; adjusted odds ratio of eGFR < 60 mL/min/1.73 m(2) in RQ/QQ versus RR carriers, 1.18; 95% confidence interval, 0.76 to 1.83). As expected, the established kidney disease risk factors hypertension and diabetes mellitus were associated strongly with measures of kidney damage/dysfunction, but the R229Q polymorphism was not associated with an additional increase in kidney disease measures. LIMITATIONS: Single measurement of ACR, subsample of all ARIC participants. CONCLUSION: No significant association of the relatively rare R229Q variant and ACR or eGFR was found in either white or black individuals. The phenotypic effect of a variant as R229Q would have to be of great magnitude to meaningfully contribute to the risk of kidney disease on a population level. The importance of such variants in the general population, as well as replication studies, can be evaluated best in large community-based studies that allow for accounting of established disease risk factors.
BACKGROUND: Rare mutations in nephrosis 2 (NPHS2), encoding podocin, are found in patients with familial and sporadic steroid-resistant nephrotic syndrome and focal segmental glomerular sclerosis. The objective of this study is to assess the contribution of the commonly reported functional podocin polymorphism R229Q to kidney disease in the population at large and replicate a prior study of an association of R229Q and albuminuria in the general population. STUDY DESIGN: Large sample of the Atherosclerosis Risk in Communities (ARIC) Study, a population-based prospective study. SETTING & PARTICIPANTS: 4,424 white and 3,746 black middle-aged adults. PREDICTOR: Genotype at the R229Q polymorphism in podocin. OUTCOMES: Urinary albumin-creatinine ratio (ACR) and decreased estimated glomerular filtration rate (eGFR) as measures of kidney damage/dysfunction. MEASUREMENTS: Crude and multivariable adjusted linear and logistic regression models. RESULTS:R229Q allele frequencies were 3.7% in 4,424 white and 0.6% in 3,746 black individuals. No significant association of R229Q with increased ACR or decreased eGFR was observed (adjusted odds ratio of ACR > or = 30 mg/g in RQ/QQ versus RR carriers, 1.18; 95% confidence interval, 0.76 to 1.84; adjusted odds ratio of eGFR < 60 mL/min/1.73 m(2) in RQ/QQ versus RR carriers, 1.18; 95% confidence interval, 0.76 to 1.83). As expected, the established kidney disease risk factors hypertension and diabetes mellitus were associated strongly with measures of kidney damage/dysfunction, but the R229Q polymorphism was not associated with an additional increase in kidney disease measures. LIMITATIONS: Single measurement of ACR, subsample of all ARIC participants. CONCLUSION: No significant association of the relatively rare R229Q variant and ACR or eGFR was found in either white or black individuals. The phenotypic effect of a variant as R229Q would have to be of great magnitude to meaningfully contribute to the risk of kidney disease on a population level. The importance of such variants in the general population, as well as replication studies, can be evaluated best in large community-based studies that allow for accounting of established disease risk factors.
Authors: Hiroyasu Tsukaguchi; Akulapalli Sudhakar; Tu Cam Le; Trang Nguyen; Jun Yao; Joshua A Schwimmer; Asher D Schachter; Esteban Poch; Patricia F Abreu; Gerald B Appel; Aparecido B Pereira; Raghu Kalluri; Martin R Pollak Journal: J Clin Invest Date: 2002-12 Impact factor: 14.808
Authors: Gianluca Caridi; Roberta Bertelli; Francesco Scolari; Simone Sanna-Cherchi; Marco Di Duca; Gian Marco Ghiggeri Journal: Kidney Int Date: 2003-07 Impact factor: 10.612
Authors: Gianluca Caridi; Roberta Bertelli; Alba Carrea; Marco Di Duca; Paolo Catarsi; Mary Artero; Michele Carraro; Cristina Zennaro; Giovanni Candiano; Luca Musante; Marco Seri; Fabrizio Ginevri; Francesco Perfumo; Gian Marco Ghiggeri Journal: J Am Soc Nephrol Date: 2001-12 Impact factor: 10.121
Authors: Gianluca Caridi; Roberta Bertelli; Marco Di Duca; Monica Dagnino; Francesco Emma; Andrea Onetti Muda; Francesco Scolari; Nunzia Miglietti; Gianna Mazzucco; Luisa Murer; Alba Carrea; Laura Massella; Gianfranco Rizzoni; Francesco Perfumo; Gian Marco Ghiggeri Journal: J Am Soc Nephrol Date: 2003-05 Impact factor: 10.121
Authors: Josef Coresh; Brad C Astor; Geraldine McQuillan; John Kusek; Tom Greene; Frederick Van Lente; Andrew S Levey Journal: Am J Kidney Dis Date: 2002-05 Impact factor: 8.860
Authors: Guruprasad Manjunath; Hocine Tighiouart; Hassan Ibrahim; Bonnie MacLeod; Deeb N Salem; John L Griffith; Josef Coresh; Andrew S Levey; Mark J Sarnak Journal: J Am Coll Cardiol Date: 2003-01-01 Impact factor: 24.094
Authors: Alexandre C Pereira; Aparecido B Pereira; Glória F Mota; Roberto S Cunha; Fernando L Herkenhoff; Martin R Pollak; José G Mill; José E Krieger Journal: Kidney Int Date: 2004-03 Impact factor: 10.612
Authors: Linus Butt; David Unnersjö-Jess; Martin Höhne; Robert Hahnfeldt; Dervla Reilly; Markus M Rinschen; Ingo Plagmann; Paul Diefenhardt; Sebastian Brähler; Paul T Brinkkötter; Hjalmar Brismar; Hans Blom; Bernhard Schermer; Thomas Benzing Journal: J Am Soc Nephrol Date: 2021-12-01 Impact factor: 10.121
Authors: Philippe Pierre Robichaud; Eric P Allain; Sarah Belbraouet; Claude Bhérer; Jean Mamelona; Jason Harquail; Stéphanie Crapoulet; Nicolas Crapoulet; Mathieu Bélanger; Mouna Ben Amor Journal: BMC Med Genomics Date: 2022-04-29 Impact factor: 3.622
Authors: Michelle T P Riguetti; Patrícia Varela; Danilo E Fernandes; M Goretti Polito; Fernanda M Casimiro; João B Pesquero; Gianna Mastroianni-Kirsztajn Journal: Front Genet Date: 2020-09-16 Impact factor: 4.599